Business Context and Reporting Period
Company: Stevanato Group S.p.A.
Filing Type: Form 6-K (Interim Condensed Consolidated Financial Statements)
Reporting Period: Three and six months ended June 30, 2021
Filing Date: August 23, 2021
Business Overview: A global provider of drug containment, drug delivery, and diagnostic solutions. Operations are divided into two segments: Biopharmaceutical and Diagnostic Solutions (containment, delivery systems, medical devices) and Engineering (machinery for manufacturing and inspection). The company operates in over 70 countries with production plants in Italy, Germany, Slovakia, the U.S., Mexico, China, and Denmark.
Key Financial Metrics (Six Months Ended June 30, 2021)
| Metric | 2021 (EUR '000) | 2020 (EUR '000) |
|---|---|---|
| Revenues | 396,813 | 298,242 |
| Gross Profit | 129,099 | 88,354 |
| Gross Margin | 32.5% | 29.6% |
| Operating Profit | 90,534 | 42,520 |
| Operating Margin | 22.8% | 14.3% |
| Net Profit | 71,031 | 27,947 |
| Net Profit Margin | 17.9% | 9.4% |
| EBITDA | 116,900 | 68,200 |
| Free Cash Flow | 15,800 | 3,100 |
| Cash and Cash Equivalents | 100,786 | 115,599 |
| Total Debt (Financial Liabilities) | 345,229 | 375,358 |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased by 33.1% (€98.6 million) to €396.8 million. On a constant currency basis, growth was 36.3%.
- Biopharmaceutical Segment: Revenue rose 27.6% to €335.4 million, driven by high-value solutions (+36.9%) and increased demand for vaccine-related products (vials, syringes).
- Engineering Segment: Revenue surged 73.4% to €61.4 million, primarily due to higher sales of visual inspection systems and glass forming machines.
- Profitability Expansion: Operating profit more than doubled (+112.9%) to €90.5 million. Net profit attributable to equity holders increased 152.7% to €71.0 million.
- Margins: Gross margin improved to 32.5% due to a favorable product mix (higher proportion of high-value solutions) and production efficiencies.
- Expense Management: General and Administrative (G&A) expenses decreased by 30.6% to €20.0 million, largely due to a non-recurring accrual reversal of €9.9 million related to the early termination of legacy incentive plans.
- Working Capital: Cash flow from operating activities improved significantly to €60.0 million (from €44.6 million in 2020), though net cash decreased by €16.6 million due to high capital expenditures (€45.4 million) and dividend payments (€11.2 million).
Guidance, Outlook, and Risks
- Outlook: Management anticipates demand for syringes, vials, and related products will remain elevated as global vaccination programs continue. The company is investing in capacity expansion (new plants in the U.S. and China) and strategic acquisitions.
- Recent Capital Event: On July 16, 2021, the company completed its IPO on the NYSE (Symbol: STVN), raising approximately $453.5 million in net proceeds (including over-allotment). Proceeds will fund capacity expansion and M&A.
- Key Risks:
- Currency Fluctuations: Significant exposure to USD, BRL, and MXN. Unfavorable currency movements negatively impacted reported revenue growth in 2021.
- Customer Concentration: While no single customer exceeded 10% of revenue in H1 2021, the business relies on relationships with major pharmaceutical companies.
- Supply Chain & Operations: Risks related to raw material availability, energy costs, and potential operational interruptions.
- Backlog Reliability: Backlog increased to €739 million, but management notes it is not a reliable indicator of future revenue due to potential delays or cancellations.
Investor Verification Checklist
- Non-Recurring Items: Verify the sustainability of the €9.9 million G&A expense reduction (incentive plan reversal) and the €5.5 million tax saving from the "Patent Box" regime agreement.
- Currency Impact: Assess the sensitivity of future earnings to USD and BRL exchange rates, as these currencies negatively impacted H1 2021 results.
- Capital Allocation: Monitor the deployment of the ~$453 million IPO proceeds, specifically the timeline for new greenfield plants in Indiana and China.
- Backlog Conversion: Track the conversion rate of the €739 million backlog into recognized revenue, noting the risk of project delays.
- Debt Profile: Review the leverage ratio (Net Debt/EBITDA was 1.0x as of June 30, 2021) and upcoming debt maturities.